AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22512461
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing (SRP) plus systemic amoxicillin + metronidazole (SMA)
Trial: 22512461
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing (SRP) plus no adjunctive treatment
Trial: 12809960
Drug: Orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat 120 mg TID with Fluvastatin 80 mg/d
Trial: 8674343
Drug: Normothermic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normothermic treatment group
Trial: 30608337
Drug: Maggot therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maggot therapy (MT)
Trial: 27253669
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral contraceptive pill (OCP)
Trial: 24297663
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) 50 mg/day
Trial: 20709087
Drug: 800ml of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800ml of paper filtered coffee daily for 5 days
Trial: 12062881
Drug: Low-dose haloperidol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose haloperidol (mean dose 5.0 mg at 6 months)
Trial: 12062881
Drug: Risperidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (mean dose 6.0 mg at 6 months)
Trial: 9088582
Drug: Zolmitriptan single
RxNorm normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zolmitriptan single dose 10 mg
Trial: 29788346
Drug: Ebola vaccine
RxNorm normalized name: ebola vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebola vaccine
Trial: 24518169
Drug: Early insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early insulin treatment
Trial: 18180864
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine added to current oral antidiabetic drugs (OAD) regimen
Trial: 18180864
Drug: Increased dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dosage of oral antidiabetic drugs (OAD)
Trial: 15858073
Drug: Phonics treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phonics treatment package
Trial: 12650495
Drug: Suprascapular nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprascapular nerve block with 5 mL 0.5% bupivacaine with epinephrine
Trial: 12650495
Drug: Piroxicam patch
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroxicam patch (48 mg) applied to each shoulder
Trial: 10792383
Drug: HAART plus
RxNorm normalized name: Tri-Heart Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART plus low dose rIL-2 (1000 000 U/daily) (n = 8)
Trial: 8680492
Drug: Jet injector
RxNorm normalized name: Jet Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jet injector for morphine (8 mg, 5 mg if weight ≤ 65 kg)
Trial: 8680492
Drug: Needle and
RxNorm normalized name: syringe with needle and cannula, disposable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle and syringe for morphine (8 mg, 5 mg if weight ≤ 65 kg)
Trial: 8680492
Drug: Jet injector
RxNorm normalized name: Jet Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jet injector for heparin (3500 U every 8 hours for 5 days)
Trial: 8680492
Drug: Needle and
RxNorm normalized name: syringe with needle and cannula, disposable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle and syringe for heparin (3500 U every 8 hours for 5 days)
Trial: 1847278
Drug: Succinylcholine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (1 mg/kg) plus Pancuronium (100 micrograms/kg)
Trial: 1847278
Drug: Succinylcholine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (1 mg/kg) plus Pipecuronium (80 micrograms/kg)
Trial: 23270288
Drug: Fränkel II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fränkel II appliance treatment for 1 year 11 months
Trial: 20231536
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of ramipril and telmisartan
Trial: 12645641
Drug: New devices
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New devices (thrombectomy devices, drug-eluting stents)
Trial: 10484395
Drug: Active rectal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active rectal distension
Trial: 10484395
Drug: Sham rectal
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham rectal distension
Trial: 9139277
Drug: Responsive patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Responsive patients (on one or two drugs)
Trial: 9139277
Drug: Resistant patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant patients (on three or more drugs)
Trial: 9139277
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with essential hypertension resistant to treatment
Trial: 9139277
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with essential hypertension responsive to antihypertensive treatment
Trial: 6315911
Drug: Marijuana (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marijuana (20 mg doses of delta‐9 tetrahydrocannabinol)
Trial: 31542292
Drug: Early combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early combination therapy with vildagliptin (50 mg twice daily) and metformin (stable daily dose of 1000 mg, 1500 mg, or 2000 mg)
Trial: 31542292
Drug: Initial metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial metformin monotherapy (stable daily dose of 1000 mg, 1500 mg, or 2000 mg) and placebo twice daily
Trial: 31542292
Drug: Early combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early combination therapy with vildagliptin and metformin
Trial: 31542292
Drug: Initial metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial metformin monotherapy
Trial: 16522696
Drug: Oral conivaptan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral conivaptan 40 mg/d
Trial: 16522696
Drug: Oral conivaptan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral conivaptan 80 mg/d
Trial: 30103252
Drug: Oral apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral apixaban
Trial: 31456010
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mizolastine (10 mg/day), proteoglycan (1.2 g, 3 times/day), calcium gluconate (10 mg/day), vitamin D3 (10 mg/week)
Trial: 31456010
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mizolastine and proteoglycan
Trial: 23928867
Drug: Metformin added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin added to intensive insulin therapy
Trial: 19538812
Drug: 300 g
RxNorm normalized name: Zantac 300 GELdose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 g additional fruit and vegetables per day
Trial: 18856162
Drug: Efalizumab therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab therapy
Trial: 2659104
Drug: Salvage hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salvage hormonal therapy
Trial: 2659104
Drug: Retreatment with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retreatment with CFP as salvage chemotherapy
Trial: 28154373
Drug: Tiotropium +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium + Olodaterol 2.5/5 or 5/5 μg
Trial: 28154373
Drug: Tiotropium 2.5
RxNorm normalized name: TIOTROPIUM 2.5MCG/ACTUAT 60D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 2.5 or 5 μg
Trial: 28154373
Drug: Tiotropium +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium + Olodaterol 5/5 μg
Trial: 18437797
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading of implants
Trial: 20467635
Drug: Early loading
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early loading of implants
Trial: 14652118
Drug: Propofol at
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol at a subhypnotic dose (1.0 mg/kg/hr)
Trial: 11742887
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (5 mg) plus pyridoxine (250 mg)
Trial: 8498758
Drug: Minocycline, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline, 100 mg nightly for 7 days
Trial: 8498758
Drug: Doxycycline, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline, 100 mg twice daily for 7 days
Trial: 3281765
Drug: Saline bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline bolus followed by saline infusion
Trial: 3281765
Drug: 0.4 microgram.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 microgram.kg‐1 naloxone bolus followed by 0.4 microgram.kg‐1.hr‐1 naloxone infusion
Trial: 3281765
Drug: 2.0 micrograms.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 micrograms.kg‐1 naloxone bolus followed by 2.0 micrograms.kg‐1.hr‐1 naloxone infusion
Trial: 3281765
Drug: 4.0 micrograms.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 micrograms.kg‐1 naloxone bolus followed by 4.0 micrograms.kg‐1.hr‐1 naloxone infusion
Trial: 29145038
Drug: Molecular targeted
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular targeted agents (MTAs)
Trial: 30271119
Drug: Other molecular
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Other molecular targeted agents (MTAs)
Trial: 29132441
Drug: Early screening
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early screening and treatment for genital Chlamydia trachomatis infection over 24 months.
Trial: 25160589
Drug: MK‐3577 (0‐900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK‐3577 (0‐900 mg)
Trial: 25160589
Drug: Glucagon, octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon, octreotide (Sandostatin), and basal insulin infusion
Trial: 20017187
Drug: Higher baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher baseline pain intensity, Hispanic ethnicity, and taking cumulative daily rest time of 35 min or more
Trial: 9497653
Drug: Tetracycline‐Hcl solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline‐Hcl solution 100 mg/ml for 5 minutes
Trial: 2158192
Drug: Phyllanthus amarus
RxNorm normalized name: Phyllanthus amarus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phyllanthus amarus extract, administered orally for 1 month
Trial: 2559794
Drug: Phyllanthus amarus
RxNorm normalized name: Phyllanthus amarus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phyllanthus amarus extract, administered intraperitoneally
Trial: 27219124
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C (3 g in 500 mL of Ringer)
Trial: 27219124
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (6 mL in 500 mL of Ringer)
Trial: 20350769
Drug: Lipid-lowering treatment
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering treatment (LLT) group, including statin and/or fibrate
Trial: 20350769
Drug: No-Lipid-lowering treatment
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-Lipid-lowering treatment (No-LLT) group
Trial: 12671333
Drug: Vigorous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigorous treatment of hypertension and use of converting‐enzyme inhibitors
Trial: 1718694
Drug: Intrarenal gallopamil
RxNorm normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrarenal gallopamil plus intravenous furosemide (0.5 mg/kg/h for 24 hours)
Trial: 6958406
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of preventive regimens including fluoridated water ingestion, oral hygiene education, dental examinations, prophylaxis, acidulated phosphate fluoride gel (1.23%), pit and fissure sealants, and restorative care
Trial: 6958406
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group that continued with preventive regimens
Trial: 6958406
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group that did not continue with treatment after 3 years
Trial: 16484309
Drug: Ibuprofen (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (1200 mg daily during menses for up to 5 days each cycle for the first 6 months)
Trial: 2864937
Drug: etilefrine pivalate
RxNorm normalized name: etilefrine
DrugBank: Etilefrine (DB08985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etilefrine pivalate (Ep, 20 mg p.o.)
Trial: 2864937
Drug: dihydroergotamine (DHE,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dihydroergotamine (DHE, 5 mg)
Trial: 27341683
Drug: Triple Combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple Combination Therapy (TCT)
Trial: 25170594
Drug: Short-term preseasonal
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term preseasonal allergoid immunotherapy
Trial: 23787227
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioural therapy (iCBT) program (the Sadness Program)
Trial: 20595412
Drug: Adjunctive SAMe
RxNorm normalized name: SAMe
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive SAMe (800 mg/twice daily)
Trial: 16905077
Drug: L-O (lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-O (lidocaine with occlusion of IV flow)
Trial: 16905077
Drug: L-F (lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-F (lidocaine with free IV flow)
Trial: 16905077
Drug: L (lidocaine
RxNorm normalized name: Lenzagel (lidocaine hydrochloride 4 % / menthol 1 % ) Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L (lidocaine pretreatment)
Trial: 11720639
Drug: Dalteparin (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (120 IU/kg subcutaneously twice daily for more than 6 days)
Trial: 8924306
Drug: Exosurf (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exosurf (2 x 5 mL/kg doses given 12 h apart, first dose at mean age of 18.7 +/- 3.4 h)
Trial: 30785830
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy and autologous stem-cell transplantation (ASCT)
Trial: 25710565
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (LDA; 81 mg/day)
Trial: 24142681
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (G1), without any anti‐arrhythmic drug (AAD)
Trial: 21956713
Drug: Oral cholecalciferol
RxNorm normalized name: cholecalciferol Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholecalciferol 150,000 IU every 3 months (n=353)
Trial: 21956713
Drug: Oral cholecalciferol
RxNorm normalized name: cholecalciferol Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholecalciferol 150,000 IU every 3 months
Trial: 19638596
Drug: Nonprescription nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonprescription nicotine replacement therapy (NRT)
Trial: 17580251
Drug: Molecular tools
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular tools for diagnosis and treatment of aortic disease
Trial: 15231009
Drug: 10 kcal/kgLBM/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 kcal/kgLBM/day energy availability treatment
Trial: 15231009
Drug: All restricted
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All restricted energy availability treatments (10, 20, or 30 kcal/kgLBM/day)
Trial: 15231009
Drug: Energy availability
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy availability treatments (20 and 30 kcal/kgLBM/day)
Trial: 15231009
Drug: Energy availability
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy availability treatments
Trial: 7744561
Drug: 1 microT
RxNorm normalized name: BABESIA MICROTI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microT (10 mG) electromagnetic fields applied over the right temporal lobe
Trial: 7744561
Drug: 1 microT
RxNorm normalized name: BABESIA MICROTI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microT (10 mG) electromagnetic fields applied over the left temporal lobe
Trial: 7744561
Drug: 1 microT
RxNorm normalized name: BABESIA MICROTI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microT (10 mG) electromagnetic fields applied over both temporal lobes
Trial: 2688995
Drug: Nasal salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal salmon calcitonin (200 IU daily) with daily calcium supplement of 500 mg
Trial: 4574042
Drug: Prophylactic C.N.S.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic C.N.S. treatment (craniospinal irradiation plus intrathecal methotrexate)
Trial: 4574042
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic C.N.S. treatment
Trial: 20681811
Drug: Hydroxyapatite (HAP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyapatite (HAP) in dry sol gel form
Trial: 9316825
Drug: Buprenorphine 0.3
RxNorm normalized name: buprenorphine 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 0.3 mg/70 kg
Trial: 380610
Drug: Morphine 10
RxNorm normalized name: morphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 10 mg/70 kg
Trial: 8352699
Drug: Lovastatin (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (20-40 mg)
Trial: 3528611
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (mean dose 7.8 +/- 1.2 mg/kg/day)
Trial: 31301105
Drug: 4-mm HIGH
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-mm HIGH treatment
Trial: 31301105
Drug: 4-mm LOW
RxNorm normalized name: Dianeal Low Calcium 4.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-mm LOW treatment
Trial: 31301105
Drug: 6-mm HIGH
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-mm HIGH treatment
Trial: 31375879
Drug: Niraparib 300
RxNorm normalized name: niraparib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib 300 mg daily with bevacizumab 15 mg/kg every 21 days
Trial: 31375879
Drug: Bevacizumab 15
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 15 mg/kg every 21 days
Trial: 27137713
Drug: Epelsiban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epelsiban (10 to 200 mg single-dose; 10 to 150 mg repeat-dose)
Trial: 22559997
Drug: Triple test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple test with two antibiotics and one NSAID or two NSAIDs and one antibiotic performed on the same day (n=22)
Trial: 22559997
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with drugs taken on three separate days (n=20)
Trial: 21654249
Drug: Electrolyzed strongly
RxNorm normalized name: Strongid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrolyzed strongly acidic aqueous solution
Trial: 19386683
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg daily for 5 days
Trial: 12220769
Drug: Flaxseed (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed (40 g/day)